Literature DB >> 21607635

Intraoperative conversion rate to a large, limbal opening in minimally invasive strabismus surgery (MISS).

Marion Kaup1, Stefania M Mojon-Azzi, Andrea Kunz, Daniel S Mojon.   

Abstract

BACKGROUND: To evaluate which factors predispose to an intraoperative conversion to the usual limbal approach in minimally invasive strabismus surgery (MISS).
METHODS: This study included 451 consecutive patients operated on by one surgeon at Kantonsspital St Gallen, Switzerland, with minimally invasive rectus muscle surgery between February 2003 and December 2007. We evaluated the intraoperative conversion rate to the usual limbal approach over time, and performed a retrospective determination of date of surgery, age of patient, motility of the eye, primary or revision surgery, and the type and dose of surgery in 982 consecutive rectus muscle procedures.
RESULTS: In 3.6% (35/982) of MISS procedures, an intraoperative conversion to a large, limbal approach was necessary. The overall conversion rate decreased over time, from 8.4% in 2003 to 0.4% in 2007. The multivariate regression analysis showed a significant negative influence between the date of surgery and the conversion rate (p < 0.005). Muscle resections were associated with a higher conversion rate (p < 0.001). The other evaluated factors had no significant influence on an intraoperative enlargement of the conjunctival opening.
CONCLUSIONS: This study confirms the reliability of the new MISS technique, and shows a low conversion rate to the usual limbal approach. The conversion rate decreased over time with increasing surgical experience. Muscle resections were associated with a higher conversion rate, while the age of the patient, the motility of the eye, revision surgery and the dose of surgery had no significant influence on an intraoperative conversion.

Entities:  

Mesh:

Year:  2011        PMID: 21607635     DOI: 10.1007/s00417-011-1707-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Recession under Tenon's capsule.

Authors:  K C SWAN; T TALBOT
Journal:  AMA Arch Ophthalmol       Date:  1954-01

2.  Comparison of a new, minimally invasive strabismus surgery technique with the usual limbal approach for rectus muscle recession and plication.

Authors:  D S Mojon
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

3.  Comparison of a new, minimally invasive strabismus surgery technique with the usual limbal approach for rectus muscle recession and plication.

Authors:  B J Kushner
Journal:  Br J Ophthalmol       Date:  2007-01       Impact factor: 4.638

4.  Minimally invasive strabismus surgery.

Authors:  D S Mojon
Journal:  Br J Ophthalmol       Date:  2009-06       Impact factor: 4.638

5.  The paralimbal approach with deferred conjunctival closure for adjustable strabismus surgery.

Authors:  A P Santiago; S J Isenberg; D Neumann; A Spierer
Journal:  Ophthalmic Surg Lasers       Date:  1998-02

6.  The limbal approach to surgery of the rectus muscles.

Authors:  G K Von Noorden
Journal:  Arch Ophthalmol       Date:  1968-07

7.  A modified technique for rectus muscle plication in minimally invasive strabismus surgery.

Authors:  Daniel S Mojon
Journal:  Ophthalmologica       Date:  2009-11-24       Impact factor: 3.250

8.  The learning curve for primary vitrectomy without scleral buckling for pseudophakic retinal detachment.

Authors:  Brice Dugas; Pierre-Olivier Lafontaine; Alexandre Guillaubey; Jean-Paul Berrod; Isabelle Hubert; Alain M Bron; Catherine P Creuzot-Garcher
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-26       Impact factor: 3.117

9.  Radial incision for surgery of the horizontal rectus muscles.

Authors:  G Velez
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1980 Mar-Apr       Impact factor: 1.402

10.  Minimally invasive strabismus surgery (MISS) for inferior obliquus recession.

Authors:  Daniel S Mojon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.